This HTML5 document contains 19 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/dosage/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB05351/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/patent/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n13http://linked.opendata.cz/resource/drugbank/drug/DB05351/identifier/national-drug-code-directory/
n3http://linked.opendata.cz/ontology/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB05351
rdf:type
n3:Drug
n3:description
TAK-390MR is an investigational for the treatment of acid related disorders.. TAK-390MR employs a new modified release (MR) technology on an enantiomer of lansoprazole.
n3:dosage
n7:271B41A7-363D-11E5-9242-09173F13E4C5 n7:271B41A8-363D-11E5-9242-09173F13E4C5 n7:271B41A5-363D-11E5-9242-09173F13E4C5 n7:271B41A6-363D-11E5-9242-09173F13E4C5
n3:group
investigational
n3:indication
Investigated for use/treatment in duodenal ulcers, gastric ulcers, gastroesophageal reflux disease (GERD), and gastrointestinal diseases and disorders (miscellaneous).
owl:sameAs
n6:DB05351
dcterms:title
TAK-390MR
adms:identifier
n12:DB05351 n13:54868-5998
n3:mechanismOfAction
Lansoprazole has an asymmetric sulfur in its chemical structure and is commercially marketed as a racemic mixture. Both the (R)- and (S)-enantiomers of lansoprazole inhibit acid formation in isolated canine parietal cells and (H'+'/K'+')-ATPase in canine gastric microsomes with nearly the same potency.
n3:patent
n4:1327010 n4:2375201 n4:6462058
n3:synonym
dexlansoprazole
n8:hasATCCode
n9:A02BC06
n3:category